Primary breast lymphoma
ICD-10 C84.7 ICD-11 2A81.Y

Treatment of Primary Breast Diffuse Large B Cell Lymphoma (PB-DLBCL)

Clinical scenario

Primary breast diffuse large B cell lymphoma (PB-DLBCL) is the most common presentation of primary breast lymphoma and one of its more aggressive histological subtypes. It typically presents as a rapidly enlarging breast lump, sometimes accompanied by multiple breast masses, diffuse breast enlargement, and/or enlarged axillary lymph nodes.

Treatment approach

Management of PB-DLBCL centers on a combination immunochemotherapy regimen, frequently supplemented by consolidative radiation therapy and prophylactic measures against central nervous system spread.

The complete structured protocol — including full regimen sequencing, agents, and CNS prophylaxis details — is available through the link below.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1016/j.jpra.2022.01.004

Primary breast diffuse large B cell lymphoma (PB-DLBCL) is the most common presentation of PBL (Table 1) and is one of the more aggressive histological subtypes, often presenting as a rapidly enlarging breast lump, sometimes accompanied by multiple breast masses, diffuse breast enlargement and/or enlarged axillary lymph nodes.

The most frequently administered treatment protocol for PB-DLBCL is six cycles of R-CHOP, consisting of rituximab, a monoclonal antibody targeting CD20 which acts to deplete CD20-positive cells and a regimen of four chemotherapy drugs: cyclophosphamide, doxorubicin, vincristine and prednisone.

This is often followed by consolidative radiation therapy and/or five doses of intrathecal methotrexate as a prophylactic measure for central nervous system metastasis.

View source ↗